Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

VANCOUVER, April 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the first quarter ended March 31, 2009.

"We were pleased to post solid results for our first quarter in what has been a difficult business environment for many companies," said Dr. William Hunter, President and CEO of Angiotech. "Sales in our proprietary Surgical and Interventional business areas continued to show very promising growth, with Quill SRS in particular garnering greater acceptance in new hospitals and surgical disciplines, and we continued to realize expense reductions as compared to the prior quarter. Additionally, our royalty revenue increased as compared to the fourth quarter of last year, indicating an improved market position for our partner Boston Scientific and higher sales of paclitaxel-eluting stents."

    First Quarter Financial Highlights

    -  Total revenue was $88.3 million. Total revenue was $63.2 million on
       an adjusted basis, excluding one-time license revenue of $25 million
       received from our partner Baxter International Inc. ("Baxter")
       relating to our amended and restated Distribution and License
       Agreement, as announced on March 31, 2009.

    -  Net product sales were $46.1 million.

    -  Royalty revenue was $17.1 million.

    -  Adjusted EBITDA (earnings before interest, taxes, depreciation and
       amortization, adjusted to exclude certain non-cash and non-recurring
       items) was $14.6 million.

    -  Research and development expenses were $6.1 million, and as adjusted
       to exclude non-cash stock-based compensation expenses and
       non-recurring termination related costs were $5.7 million. These
       results compare to $7.7 million and $6.9 million, respectively, in
       the fourth quarter of 
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... (NYSE Amex: CXM ) today announced plans to ... and Drug Administration (FDA) seeking marketing clearance of its ... is an advanced wound care management medical device, which ... by physicians in patients with topical wounds, which include ...
... study from Thomson Reuters released today shows explosive growth in ... rest of the world. , At this pace, China ... The study, Global Research Report: China , informs policymakers ... current place in world science. The study is part of ...
... 1 Pharmasset, Inc. (Nasdaq: VRUS ) today announced ... Association for the Study of Liver Diseases (AASLD) on Monday, ... management will review Pharmasset,s progress on the programs that are ... simultaneous webcast of this event via the internet, log on ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4China's Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 3Pharmasset to Webcast an Investor Event from the AASLD Meeting 4
(Date:4/24/2014)... play a crucial role in the global-scale cycling ... atmosphere. Now scientists at Scripps Institution of Oceanography ... forward in understanding the microscopic underpinnings of these ... make new cells, a substantial portion of that ... a buffet of edible molecules collectively called "dissolved ...
(Date:4/24/2014)... WEST LAFAYETTE, Ind. - Purdue and West Virginia University ... the golden eagle, providing a bird,s-eye view of eagle ... , Their study calls into question long-held assumptions ... not be as sensitive to ultraviolet light as previously ... have a sharper sense of smell than researchers realized. ...
(Date:4/24/2014)... a commercially important sugar used as a sweetener, ... for synthesizing riboflavin and several antiviral drugs. Genetic ... the bacteria,s ability to produce D-ribose is a ... of this valuable chemical, as described in an ... journal from Mary Ann Liebert, Inc., publishers. The ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3Genome yields insights into golden eagle vision, smell 2
... program that trains emergency medical service technicians (EMS) to read ... and expedite treatment for the severe heart condition known as ... attack, has excellent results and should become the standard of ... of the Canadian Journal of Cardiology . ...
... cells organized in thousands of small divots. Hit these cells ... candidate for a cancer drug. But a review published this ... argues that these 2D models in fact offer very ... and may often give researchers misleading results. "Up ...
... scientific research has deep roots in the history of ... off spectacularly from launch pads across the disciplines of ... and a sea change in a scientific culture now ... science, crowd-sourced science, DIY research, volunteer monitoring, community participatory ...
Cached Biology News:ECGs administered by paramedics can speed treatment for severe heart attacks 2ECGs administered by paramedics can speed treatment for severe heart attacks 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Inaugural cross-disciplinary Public Participation in Scientific Research conference 2